Statera BioPharma Profit Margin

The latest profit margin for STAB is -2829.37% as of September 2022. That compares with -6178.0% in the prior-year period — up 54.2% year over year. That is below the Healthcare sector average of 19.13%. Investors often review this figure alongside Statera BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, STAB's profit margin moved from -6178.0% to -2829.37% — a 54.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Statera BioPharma's valuation or profitability profile.

Against Healthcare companies, STAB currently prints -2829.37% for profit margin, while the sector average sits near 19.13%. That is roughly 14889.2% below the sector mean. Large gaps often invite a closer look at Statera BioPharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Statera BioPharma converts resources into returns. At -2829.37%, STAB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -6178.0% in the prior-year period — up 54.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting STAB's profit margin (-2829.37%), review year-over-year change from -6178.0%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.